Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $4.98 Analyst target: $21.20 Upside: 325.70%
Cingulate Inc., a clinical-stage biopharmaceutical company, is focused on developing candidate products for the treatment of neurobiological and central nervous system disorders. The company is headquartered in Kansas City, Kansas.
See the full interactive analysis & chart →Informational only — not investment advice.